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Franc¸ois Huaux, MD,d and Olivier Vandenplas, MD, PhDb,c Montreal, Quebec, Canada, and Yvoir and Brussels, Belgium
Background: The added value of fractional exhaled nitric oxide
(FENO) remains controversial in the investigation of
occupational asthma (OA).
Objective: We sought to assess whether or not the increase of
FENO levels following positive specific inhalation challenge (SIC)
was restricted to phenotypes of subjects sharing common
clinical characteristics by using a statistical cluster analysis.
Methods: Subjects were investigated for possible OA in a
tertiary center using SICs from 2006 to 2012. FENO levels and
sputum eosinophil counts were assessed at baseline and 24 hours
after SIC. We performed a 2-step cluster analysis of the
subgroup of subjects with OA. A multivariate logistic regression
was performed in order to identify the variables associated with
an increase in FENO in subjects with OA.
Results: One hundred and seventy-eight subjects underwent
SIC; 98 had a positive test. The cluster analysis performed in
the OA subgroup identified 3 clusters. Despite a positive SIC,
there was no increase in the FENO levels after exposure to
occupational agents in Cluster 3, in which subjects were only
exposed to low-molecular-weight (LMW) agents. The molecular
weight of the agent (high molecular weight vs LMW) was
the only factor associated with an increase in FENO (OR: 4.2
[1.1-16.8]) in subjects with a positive SIC.
Conclusion: An increase in FENO after exposure to agents
causing OA seems to occur more consistently in subjects with
OA caused by high molecular weight than in those with OA due
to LMW. (J Allergy Clin Immunol 2014;134:1063-7.)
Key words: Asthma, bronchial provocation tests, eosinophils,
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Establishing or excluding a diagnosis of immunologically
mediated (or sensitizer-induced) occupational asthma (OA) re-
quires a high level of accuracy, because the condition is associated
with significant health and socioeconomic impacts.1 Over the past
2 decades, there has been growing interest in the noninvasive
assessment of eosinophilic airway inflammation through sputum
cell analysis and the measurement of fractional exhaled nitric
oxide (FENO) as complementary tools to conventional lung
function tests in the diagnosis and management of asthma.2
Sputum cell counts have been shown to be useful as an additional
tool in the investigation of OA.3 However, sputum induction and
processing are time-consuming and require technical expertise
and thus are available in only a limited number of centers. The
measurement of FENO as a surrogate marker for eosinophilic
airway inflammation is simple and feasible in almost all patients
and provides immediate results, but it is more sensitive to
confounding factors, such as smoking, atopy, and treatment
with inhaled corticosteroids (ICS), as compared with sputum
eosinophil counts.4 Its added value in the investigation of OA
remains controversial due to conflicting data published in the
literature.5 One of the reasons for the discrepancies between the
studies may pertain to the different phenotypes of patients
included in those studies. As previously demonstrated, the atopic
status of the subjects, as well as their treatment with ICS, are
likely to influence the results obtained. Some studies looked at
OA induced by a variety of agents,6 whereas others focused on
OA due to a single agent such as isocyanates.7
The aim of this study was to assess whether or not the increase
of FENO levels following positive specific inhalation challenge
(SIC) was restricted to phenotypes of subjects sharing common
clinical characteristics by using a statistical cluster analysis.
METHODS
Study design and population
This was a prospective observational study that included consecutive
subjects who had been investigated for possible OA in a tertiary center
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(CHU Mont-Godinne) through the performance of a SIC from 2006 to 2012.
There was no exclusion criteria, as the intent of this real-life situation study
was to include the whole population of subjects investigated during a 6-year
time frame in order to have a representative sample of a day-to-day practice in
a center specializing in the field of OA. Measurements of airway hyper-
responsiveness (AHR) to histamine and assessment of FENO and sputum
eosinophil counts were performed at baseline and 24 hours after inhalation
challenge exposures to a control substance and the suspected occupational
agent. The study protocol was approved by the Comite d’Ethique Medicale
of the Centre Hospitalier Universitaire de Mont-Godinne (approval number
B03920072360). The subjects signed a statement of informed consent.
Procedures
Specific inhalation challenges. SICs were carried out
according to a previously described protocol.8-11 Briefly, occupational agents
were generated in 5 m3 cubicles using a realistic approach.11,12 The realistic
approach aims to mimic the work environment as much as possible. For
example, a baker is asked to toss flour from one tray to the other to produce
airborne particles. This approach for performing SICs has been shown to be
safe and rarely induce severe asthmatic reactions requiring administration
of systemic steroids.9 The concentrations of the agents generated during the
SIC procedures were not quantified, with the exception of SIC with
isocyanates, in which the concentrations were kept below the short-term limit
value of 20 ppb. Asthma medications were withdrawn according to their
duration of action,13 while inhaled corticosteroids were halted 72 hours prior
to the tests.
On the first day, the subjects were exposed to a ‘‘control’’ agent for 30
minutes to ensure that FEV1 fluctuations were <_12% of the baseline value. The
‘‘control’’ non-sensitizing substance was selected according to the nature of
the occupational agent suspected of causing OA; for instance, lactose powder
for SIC with agents in powder form (flour, drugs, persulphates), pine dust for
SIC with wood dusts, vinyl gloves for SIC with latex gloves, and diluents for
polyurethane products and other resins.11 Spirometry14,15 was measured at
baseline and serially for at least 6 hours after exposure. Assessment of baseline
AHR to histamine and evaluation of inflammatory cells in induced sputum
were performed at the end of the control day.
On the following day, the subjects were challenged with the suspected
occupational agent(s). Spirometry was measured according to the same
schedule as on the control day. The duration of exposure was gradually
increased (ie, 1, 4, 10, 15, 30, and 60 minutes) until a >_20% fall in FEV1
occurred or a cumulative exposure of 2 hours on the same day was completed.
Those subjects who did not demonstrate a >_20% fall in FEV1 during the first
active challenge day systematically completed a second challenge for a
maximum of 2 to 3 hours on the following day. Additional challenges
were proposed when there was a significant (>3-fold) decrease in the
post-challenge PC20 value
16 or when an increase in sputum eosinophils
>3% was found,8 as compared with the control day values. An SIC was
considered positive when a reproducible fall in FEV1 of 20% or more as
compared to pre-challenge value was recorded.
Assessment of nonspecific airway hyperrespon-
siveness. The level of AHR was assessed through the inhalation of
doubling concentrations of histamine at tidal breathing for 2-minute periods,
as described by Cockcroft et al.17 The results were expressed as the concentra-
tion of histamine inducing a 20% decrease in FEV1 (PC20). A histamine PC20
value <_16 mg/mL was considered as reflecting significant AHR. The hista-
mine PC20 was assessed at the end of the control day (ie, the baseline value)
and reassessed 6 to 8 hours after each active challenge as well as 24 hours
after the last challenge exposure, provided that FEV1 was >_90% of the
pre-challenge value. After the histamine bronchoprovocation, the subjects
were administered an inhaled bronchodilator (salbutamol 400mg) and sputum
was induced.
Sputum induction and processing. Sputum was induced by
inhaling increasing concentrations (3%, 4%, and 5%) of nebulized hypertonic
saline as previously described.6,8,18 Total cell counts and cell viability were
assessed using the trypan blue exclusion method in a Burker haemocytometer.
The sample was considered adequate for analysis when there were fewer than
20% squamous cells and viability was more than 40%. Differential cell counts
were determined by counting 400 nucleated non-squamous cells per slide on
cytospin preparations stained with May-Gr€unwald-Giemsa. The results were
expressed as the percentage of total non-squamous cells and as the absolute
number of cells in millions per mL of sputum. Sputum samples were collected
6 to 8 hours after the end of control and active challenge exposures, as well as
24 hours after the end of the last challenge exposure.
FENO measurements. FENO was measured using an online
chemiluminescence analyzer (NIOX, Aerocrine AB, Solna, Sweden) at a
flow rate of 50 mL/s, in accordance with international recommendations.19
The FENO measurement was performed before active challenges and repeated
24 hours after the challenges. These 2 values were used to compute the
increase in FENO levels during SICs based upon previous data showing that
the post-challenge increase in FENO becomes significant only at this time
point.6,7 FENO was alwaysmeasured prior to the performance of any procedure
such as spirometry, histamine challenge, sputum induction, or administration
of bronchodilators.
Analysis of data
Continuous variables were reported as mean and standard deviation except
for PC20, FENO, and sputum cell counts, which were expressed as median and
25th to 75th percentiles. A Student t test for normally distributed continuous
variables, a Mann-Whitney U test for non-normally distributed continuous
variables, and a x2 test for categorical variables were used to compare the vari-
ables of interest between groups of subjects with positive and negative SIC.
Receiver operating characteristics (ROC) curves were built in order to identify
what changes in FENO (post-exposure value – baseline value) provided the
optimal sensitivity and specificity associated with positive SIC. A 2-step clus-
ter analysis was performed because categorical and continuous variables were
used to form groups of subjects. This procedure includes a preclustering and a
hierarchical clustering of the preclusters. Standardization of all continuous
variables was made before clustering, and log-likelihood criterion was used
as distance measures. To determine the number of clusters, Schwarz Bayesian
criterion change was used, and a minimum of 10% of subjects in the smallest
cluster composition had to be observed in order to retain the final solution.
This analysis was performed using the following baseline variables: sex,
age, atopy (defined by a positive skin prick test to at least 1 of 21 common
aeroallergens), smoking habits, ICS treatment, and the change in FENO before
and after exposure in subjects with a positive SIC. The variables included in
the cluster analysis represented relevant clinical characteristics of subjects
at baseline except for the changes in FENO after exposure, which was the var-
iable of interest. Anothermodel including airway responsiveness produced the
same results but was not kept, because it decreased our sample size due to
missing variables. Sputum eosinophils could not be entered in the cluster
analysis, due to the many missing data for this variable. ANOVA for normally
distributed continuous variables, a Kruskal-Wallis test for non-normally
distributed continuous variables, and the x2 analysis for categorical measures
were used to compare the variables of interest between clusters. Correlation
analyses were performed using a Spearman rank test.
Amultivariate logistic regression analysis was conducted to assess whether
atopy (nonatopic vs atopic), smoking habits (never vs ever a smoker),
treatment with ICS (yes vs no), duration of exposure to the offending agent
during SIC, maximum fall in FEV1 during SIC, type of agent (HMW vs
LMW), baseline levels of FENO (levels below or equal to 25 ppb vs greater
than 25 ppb), and baseline FEV1 (lower than 80% vs 80% or greater) were
associated with clinically significant changes in the levels of FENO after SIC
as determined by the ROC analysis in subjects with OA. The statistical
analysis was performed with the IBM SPSS statistical software (version
19.0.0), IBM Corporation (Somers, NY). Significance was accepted when
P <_ .05.
RESULTS
One hundred and seventy-eight subjects underwent SIC, of
whom 98 showed a positive response. The characteristics of the
subjects with positive and negative SIC are presented in Table I.
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One hundred and thirty-five subjects performed NO analysis
before and after SIC. Suitable sputum samples before and after
SIC were available in 104 subjects.
There was a statistically and clinically significant difference in
FENO levels (P < .001), sputum eosinophil counts (P < .001), and
PC20 (P < .001) before and after SIC in subjects with positive
challenge. Therewas no change in sputum eosinophil counts after
SIC (P5 .36) in subjects with negative SIC. Although there was a
statistically significant difference between FENO levels (P 5 .02)
before and after challenge, these changes were minimal and were
not clinically meaningful (Table I).
Overall, therewas aweak though significant correlation between
the change in sputum eosinophil counts and FENO levels before and
after exposure to the offending agent (r 5 0.4; P < .001).
ROC for assessing the association of changes in FENO
after exposure to the offending agent and positivity
of SIC. We performed an ROC analysis to determine the
diagnostic efficiency of changes in FENO before and after SIC.
A post-challenge increase in FENO levels of 17.5 ppb or more was
associatedwith a positive SICwith a specificity of 90% and a sensi-
tivity of 45.3% (area under the curve: 0.76 0.45; P <.001) (Fig 1).
Cluster analysis in the occupational asthma sub-
group. Twenty-five subjects were not kept into the cluster
analysis due tomissing variables. Three clusters were identified in
the subjects with OA (Table II). Cluster 1 and 2 were mainly
composed of subjects exposed to HMW agents, whereas Cluster
3 was exclusively composed of subjects exposed to LMWagents.
Cluster 1 was composed of subjects with higher PC20, a trend
towards a higher FEV1, and no subjects taking ICS, compared
with Clusters 2 and 3. Clusters 1 and 2 comprised more atopic
subjects and more subjects reporting rhinitis than Cluster 3. No
significant increase in FENO levels after exposure was seen in
Cluster 3, whereas an increase in sputum eosinophil counts was
observed in the 3 clusters. Overall, there was a higher increase
in FENO levels after exposure to HMW (28.8 6 27.1 ppb) than
after exposure to LMW (9.5 6 18.4 ppb; P 5 .001) in subjects
with OA.
The multivariate logistic regression performed in order
to identify the factors associated with an increase in FENO in
subjects with OA retained only the molecular weight of the
agent (HMW) as a factor associated with an increase in
FENO (Table III).
DISCUSSION
To the best of our knowledge, this study is the first that
attempted to identify the factors associated with a change in FENO
in subjects with work-related asthma after exposure to the causal
agent. Previous studies have observed that the increase in FENO
was not uniform among subjects who experienced a positive
asthmatic reaction during SIC.20 Piipari et al showed that subjects
with elevated baseline levels and late asthmatic reactions had an
increase in FENO levels after SIC. However, this study included
only 14 subjects with OA, and results were not adjusted for
confounding factors.21
TABLE I. Characteristics of the subjects
Positive SIC Negative SIC P value
n 98 80
Age 40.05 6 10.3 41.44 6 11.2 .4
Symptoms duration (months) 38.07 6 46.9 55.5 6 71.5 .06
Asthma preceding current employment (n, %) 21 (21.4) 14 (17.5) .5
Sex, male (n, %) 60 (61.2) 46 (57.5) .6
Atopy (n, %) 62 (63.3) 34 (44.2) .01
Aeroallergens (n) Mites (32), cat (18), dog (22), tree pollen (16),
weeds (34), grass (10), molds (11)
Mites (23), (cat 9), dog (9), tree pollen (14),
weeds (16), grass (8), molds (7)
Smoking habits, 57 (58.2)/24 (245)/17 (17.3) 36 (45)/22 (27.5)/22 (27.5) .16
Never/current/ex (n, %)
Type of agent, HMW (n, %) 61 (62.2) 20 (25) <.001
Treatment with ICS (n, %) 55 (56.1) 52 (65) .3
FEV1 (% predicted) 87.4 6 13.1 90.1 6 12.7 .2
FVC (% predicted) 101.1 6 12.8 99.7 6 12.4 .4
Baseline PC20 (mg/mL) 2.5 (0.8-9.05) 10.9 (3.9-32.0) <.001
PC20 (mg/mL post-SIC) 1.12 (0.5-4.9) 8.8 (4.6-18.5) <.001
Baseline FENO (ppb, n 5 162) 28 (14.1-40,8) 13.7 (9.3-27.7) .002
Post-SIC FENO (n 5 138) 43.0 (24.5-77.3) 17 (10.7-30.2) <.001
Baseline eosinophils (%, n 5 113) 1.5 (0.9-3.9) 1.0 (0.3-2.4) .06
Post-SIC eosinophils (%, n 5 104) 7.5 (3.4-12.8) 1.0 (0.5-2.2) <.001
Results of continuous variables are represented as means 6 SDs, except for PC20, FENO, and sputum cell counts, which are presented as median (25th to 75th percentiles).
IQR, Interquartile range.
FIG 1. ROC curve assessing the association of changes in FENO before and
after exposure to the offending agent and positivity of SIC. The green line
represents the reference line and the blue line is the actual ROC curve
showing the sensitivity and specificity of each change in FENO levels associ-
ated with a positive SIC. The red dot represents the value of the change in
FENO levels associated with a high specificity for a positive SIC.
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Cluster analysis allowed identification of 3 distinct phenotypes.
Cluster 1 included milder asthmatic subjects than Clusters 2 and
3. Cluster 3 contrasted greatly with Clusters 1 and 2, with lower
number of atopic subjects, no exposure to HMW, and greater
number of late reactions. Furthermore, Cluster 3 differed the most
fromClusters 1 and 2 in terms of changes in FENO observed during
SICs; FENO changes during SICs were restricted to Clusters 1 and
2, in which the subjects were mainly exposed to HMW, whereas
no significant changes in FENO were observed in Cluster 3, which
was composed of subjects only exposed to LMW. In subjects
exposed to HMW agents, the increase in FENO was significantly
associated with a positive SIC result. Our results are consistent
with those of Pedrosa et al, who showed a high positive predictive
value of a >12% increase in FENO for a positive SIC in a small
group of subjects challenged with common allergens or HMW
agents.22
The strength of our study was to include a large cohort of
subjects, including a variety of sensitizers, which allowed to us to
identify various phenotypes among this cohort. However, this
study has several limitations that are inherent to its design as a
prospective observational study conducted in a clinical practice.
Our population included a highly heterogeneous population of
subjects with work-related asthma, with a large number of
subjects taking ICS as well as smokers. Although it has been
clearly shown that FENO measurements were influenced by those
factors, these variables did not seem to affect FENO results in a sig-
nificant way in our multivariate analysis. Our data suggest that the
changes in FENO after challenge exposure to various occupational
agents are largely affected by the type of occupational agents, and
thus probably by the different immunological mechanisms
involved in OA caused by HMW and LMW agents. However,
the study was not designed to characterize the pathophysiological
mechanisms underlying the observed differences between the
changes in FENO induced by LMWand HMWagents. The associ-
ation between an increase in FENO and exposure to HMWagents
may be due to the underlying IgE-mediated mechanism rather
TABLE II. Cluster analysis in subjects with occupational asthma
Cluster 1 Cluster 2 Cluster 3 P value
n 21 29 23
Age 35.9 6 9.8 40.2 6 10.4 45.8 6 8.7 .05
Sex, male (n, %) 14 (66.7) 19 (65.5) 10 (43.5) .2
Atopy (n, %) 16 (76.2) 22 (75.9) 8 (34.8) .003
Asthma preceding current employment (n, %) 6 (28.6) 8 (27.6) 3 (13.0) .4
Nonsmokers (n, %) 16 (76.2) 15 (51.7) 14 (60.9) .1
ICS treatment (n, %) 0 (0) 27 (93.1) 15 (65.2) <.001
Asthma symptom duration (mo) 52.6 6 56.5 51.4 6 46.3 59.2 6 101.3 .9
Rhinitis (n, %) 18 (85.7) 28 (96.6) 11 (47.8) <.001
Agent (HMW, %) 16 (76.2) 29 (100) 0 (0) <.001
Occupational agents Flour (H): 9
Enzymes (H): 2
Latex (H): 4
Linen (H): 1
Welding (L): 1
Cobalt (L): 1
Isocyanates (L): 1
Persulfate (L): 1
Platinum (L): 1
Flour: 18
Latex: 7
Tomato: 1
Cereals: 1
Enzymes: 2
Isocyanates: 3
Aldehyde: 1
Wood: 3
Welding: 1
Cleaning agents: 10
Persulfate: 1
Glue: 1
Cobalt: 1
Acrylate: 1
Ethyl acetate: 1
Type of reaction I, D, L (n, %) 16 (76.2), 3 (27.3), 2 (9.5) 15 (51.7), 6 (20.7), 8 (27.6) 10 (43.5), 2 (8.7), 11 (47.8) .06
FEV1 (% predicted) 90.8 6 13.4 83.8 6 11.6 89.9 6 15.6 .1
Baseline PC20 (mg/mL) 12.2 (1.3-30) 1.4 (0.6-8.0) 1.8 (0.8-3.7) <.001
PC20, last day (mg/mL) 5.8 (1.0-12.2) 1.1 (0.6-4.6) 0.7 (0.1-2.3) .015
Maximum FEV1 (fall, %) 34.3 6 12.7 34.6 6 14.8 29.0 6 7.1 .2
FENO baseline (ppb) 24.6 (16.2-38.0) 28.0 (14.4-58.3) 22.2 (10-33.5) .2
FENO last day (ppb) 66.0 (31.9-106,4) 48.3 (30.0-81.5) 29.0 (12.5-43.0) .001
FENO increase >_17.5 ppb (n, %) 13 (61.9) 17 (58.6) 4 (14.4) .003
Baseline eosinophil counts (%) 1.0 (0.4-1.8) 2.0 (1.0-3.5) 1.7 (1.0-5.5) .1
Eosinophil counts post-exposure (%) 6.2 (1.8-9.0) 7.2 (4.5-12.0) 7.4 (2.0-11.9) .6
Results of continuous variables are represented as means 6 SDs, except for PC20, FENO, and sputum cell counts, which are presented as median (25th-75th percentiles).
H, High-molecular-weight agent; L, low-molecular-weight agent.
TABLE III. Factors associated with a change in FENO greater
than 17.5 ppb after exposure to the offending agent in
subjects with OA
Determinant variables for a change
in FENO >17.5 ppb OR (95% CI) P value
Duration of exposure (min) 0.99 (0.9-1.0) .2
Maximum fall in FEV1 1.02 (0.9-1.1) .5
Baseline FEV1 (ref: FEV < 80%) 2.3 (0.7-8.1) .2
ICS (ref: no treatment with ICS) 1.02 (0.3-3.1) .9
Type of agent (ref: HMW) 4.2 (1.1-16.8) .04
Smoking (ref: never a smoker) 1.5 (0.5-4.3) .5
Atopy (ref: nonatopic) 2.0 (0.5-7.5) .3
Baseline FENO (ref: <_25 ppb) 0.5 (0.2-1.5) .2
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than to the type of agent itself. FENO has been shown to be
correlated with total serum IgE in asthmatic subjects.23,24 The
cohorts in which FENO had a high predictive value for asthma
were composed of subjects exposed to HMW agents or common
allergens.22 However, several studies have shown an increase in
FENO after exposure to isocyanates.7,25 Interestingly, Barbinova
et al showed an increase in FENO in subjects showing specific
IgE to isocyanates.25 Unfortunately, only 4 subjects had
isocyanate-induced asthma in our cohort, and only 3 of them
performed measurements of FENO before and after exposure,
preventing us from making any conclusion regarding this specific
agent. The methodology of SIC using a realistic approach does
not allow taking formally into account the magnitude of the
bronchial response to the occupational agent as a factor that could
influence the changes in FENO. Nevertheless, in the multivariate
logistic regression analysis, the threshold duration of exposure
required to elicit a 20% decline in FEV1 during SICs and the
maximum fall in FEV1 did not seem to significantly affect the
FENO response. Other potential confounding factors, such as
genetic polymorphism, could not be assessed in this study but
may have clinical implications.26
Sputum eosinophil counts have been shown to increase in the
majority of subjects with OA after exposure to the offending
agent. Although there was a correlation between the change in
sputum eosinophil counts and the FENO levels before and after
exposure to the offending agent, the correlation was weak in
our population. Interestingly, the 3 clusters with OA had an
increase in sputum eosinophil count after exposure, whereas an
increase in FENO was not found in Cluster 3, which included
only OA due to LMW agents. Sputum eosinophil counts have
been shown to have a better predictive value than FENO for
diagnosing OA caused by various agents.6 However, sputum
cell counts could not be obtained in 37% of our subjects. This
finding illustrates the limitation of sputum cell counts and the
need to have access to a non-invasive measure of inflammation
that can be done in the majority of subjects. This study indicates
that, when restricted to HMW, FENO represents a reliable and
suitable alternative to sputum eosinophil counts during the
investigation of OA.
In conclusion, an increase in FENO was strongly associated with
asthmatic reactions induced by HMW agents. Although the
mechanisms underlying these different patterns of FENO response
between HMW and LMW agents remain to be explored, the
results of this study provide useful information for the clinical
investigation of work-related asthma using FENO measurements
as an indirect marker of airway inflammation.
We thank Mr Jean Paquet for help with the statistical analysis.
Clinical implications: The assessment of FENO levels after
challenge or workplace exposure is likely to be more helpful
in the investigation of occupational asthma caused by high-
molecular-weight agents than by low-molecular-weight agents.
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